Jupiter Neurosciences, Inc. (JUNS) Stock

About Jupiter Neurosciences, Inc.

Jupiter Neurosciences, Inc. is led by CEO Christer Rosen, publicly traded since 2022.

Jupiter Neurosciences, Inc. (JUNS) stock trades at $2.98 with a market capitalization of $3.93M. The stock is valued at a negative price-to-earnings (P/E) ratio of -0.14, reflecting a net loss over the last twelve months, a negative price-to-book of -4.24, reflecting negative shareholders' equity, price-to-sales of 56.66. Over the past 52 weeks the stock has ranged between $2.25 and $135.75, and currently trades 97.8% below its 52-week high.

On profitability, Jupiter Neurosciences, Inc. generates a return on equity (ROE) of 747.33% (not meaningful, as shareholders' equity is negative), return on capital employed of 900.00%, an operating margin of -230.76%, a net profit margin of -226.91%.

Jupiter Neurosciences, Inc. by the numbers, 2019–2025

Between 2019 and 2025 Jupiter Neurosciences, Inc. reported revenue of $0 rising to $0. Compounded, revenue has grown —% a year over five years, —% over three, —% over the last twelve months. Net profit fell to $-9.0M.

The most recent net margin is -226.91%. On a trailing twelve-month basis to Jun '26, revenue is $0 and net profit $-9.0M.

Borrowings rose from $1.0M to $5.0M, cash from operations was $-5.0M in the latest year, positive in 0 of the last 7.

Return on equity has averaged 127.0% over five years, and was 450.0% in the most recent year.

The share price itself has compounded at —% a year over five years, —% over three, —% over the last year. Past price movement is history, not a forecast.

Figures are as reported and in the company's own reporting currency. They describe what has already happened and carry no implication about what follows.

Jupiter Neurosciences, Inc. (JUNS) — frequently asked questions